$66.95
+0.60%Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Outstanding operational efficiency. The company generates substantial profit from core operations.
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
UTMD โข NASDAQ
| Utah Medical Products, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
38.5M | 40.9M | 50.2M | 52.3M | 49.1M | 42.2M | 46.9M | 42M | 41.4M | 39.3M | 40.2M | 41.3M | 40.5M | 41.6M | 37.9M | 25.1M | 25.9M | 27.8M | 28.5M | 28.8M | |
GROSS PROFIT | ||||||||||||||||||||
(18.6M) | (16.8M) | (20.2M) | (20.1M) | (18.1M) | (16.6M) | (17.4M) | (15.7M) | (15M) | (15.6M) | (16M) | (16.3M) | (16.2M) | (16.2M) | (15.5M) | (11.9M) | (12.1M) | (12.8M) | (12.7M) | (12.6M) | |
19.9M | 24.1M | 30M | 32.2M | 30.9M | 25.5M | 29.5M | 26.3M | 26.4M | 23.7M | 24.2M | 25M | 24.3M | 25.3M | 22.4M | 13.2M | 13.8M | 15M | 15.8M | 16.1M | |
OPERATING INCOME | ||||||||||||||||||||
(8.5M) | (10.5M) | (13.3M) | (12.4M) | (12M) | (11.8M) | (11.8M) | (7.6M) | (7.4M) | (7.5M) | (8.5M) | (8.8M) | (9.4M) | (10.1M) | (10.6M) | (4.3M) | (4.4M) | (4.6M) | (5M) | (5.3M) | |
(7.8M) | (5.6M) | (12.7M) | (11.9M) | (11.5M) | (11.4M) | (11.4M) | (7.2M) | (6.9M) | (7M) | (8M) | (8.3M) | (9M) | (9.5M) | (10M) | (3.9M) | (4M) | (4.3M) | (4.7M) | (5M) | |
(668K) | (813K) | (560K) | (493K) | (526K) | (486K) | (483K) | (454K) | (447K) | (475K) | (522K) | (460K) | (491K) | (563K) | (518K) | (397K) | (361K) | (359K) | (382K) | (316K) | |
11.4M | 13.6M | 16.8M | 19.8M | 18.9M | 13.7M | 17.6M | 18.7M | 19M | 16.2M | 15.7M | 16.2M | 14.8M | 15.2M | 11.8M | 8.9M | 9.4M | 10.4M | 10.8M | 10.8M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (65K) | (289K) | (438K) | (652K) | (859K) | (25K) | (51K) | (198K) | (0.0) | (0.0) | |
0.0 | 3.4M | 0.0 | 661K | 166K | 112K | 0.0 | 0.0 | 0.0 | 0.0 | -65K | -289K | -438K | -652K | -859K | -25K | 155K | 345K | 0.0 | 0.0 | |
(0.0) | (4.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (54K) | (0.0) | -46K | (0.0) | (79K) | -17K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -1K | |
2.7M | 3.2M | 3.3M | 869K | 181K | 132K | 252K | 762K | 71K | 235K | -106K | -390K | -352K | -659K | -762K | 118K | 148K | 388K | 1.3M | 1.6M | |
14.1M | 16.8M | 20.1M | 20.7M | 19.1M | 13.8M | 17.9M | 19.5M | 19.1M | 16.4M | 15.5M | 15.8M | 14.5M | 14.5M | 11.1M | 9M | 9.6M | 10.8M | 12M | 12.4M | |
NET INCOME | ||||||||||||||||||||
(2.8M) | (2.9M) | (3.5M) | (4.2M) | (4.3M) | (3M) | (3.2M) | (904K) | (10.6M) | (4.3M) | (3.7M) | (4.4M) | (3.1M) | (4.4M) | (3.7M) | (3M) | (3.3M) | (3.6M) | (4.1M) | (4.3M) | |
11.3M | 13.9M | 16.6M | 16.5M | 14.8M | 10.8M | 14.7M | 18.6M | 8.5M | 12.1M | 11.8M | 11.4M | 11.4M | 10.2M | 7.4M | 6M | 6.3M | 7.2M | 7.9M | 8.2M |
UTMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 02, 2026 | April 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 23, 2025 | October 23, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 |
Continue your UTMD research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.